SEC Form 4 · accession 0001144204-16-088709
Celator Pharmaceuticals Inc · CPXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence David Mayer
Officer — President and Head of Research
Period of report
Mar 15, 2016
Accepted (ET)
Mar 17, 2016 · 4:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001327467
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2016 | M | 48,002 | $2.25 | A | 119,596 | D | |
| Common Stock | Mar 15, 2016 | F | 12,081 | $8.94 | D | 107,515 | D | |
| Common Stock | holding | — | — | — | 7,468 | I | By spouse | |
| Common Stock | holding | — | — | — | 3,631 | I | By spouse's trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option, Right to BuyF1 | $2.25 | Mar 15, 2016 | M | 48,002 | D | — | Mar 22, 2016 | Common Stock | 48,002 | 0 | D |
Explanation of responses
- F1These options are fully exercisable.